Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
| Business Activity | PASS |
| Debt Ratio (0.36%) | FAIL |
| Cash Ratio (0.00%) | PASS |
| Receivables Ratio (0.17%) | PASS |
| Revenue Ratio (0.02%) | PASS |
| Overall | FAIL |
| Date | EPS Est. | Reported EPS | Surprise % |
|---|---|---|---|
| 2026-07-22 | 5.72 | Pending | -- |
| 2026-04-23 | 5.24 | 5.44 | +3.8% |
| 2026-01-29 | 5.20 | 5.21 | +0.2% |
| 2025-10-22 | 5.50 | 5.79 | +5.3% |
| 2025-07-23 | 5.23 | 5.36 | +2.5% |
| 2025-04-23 | 5.10 | 5.15 | +0.9% |
| 2025-01-30 | 5.94 | 6.10 | +2.7% |
| 2024-10-23 | 5.25 | 5.28 | +0.5% |
| Period | Revenue | Net Income | EBITDA | Gross Profit | Op. Income | EPS |
|---|---|---|---|---|---|---|
| 2026-03-31 | $11.0B | $1.7B | $2.8B | $4.4B | $1.9B | 4.44 |
| 2025-12-31 | $12.2B | $2.0B | $3.2B | $5.0B | $2.3B | 5.22 |
| 2025-09-30 | $11.1B | $1.6B | $2.8B | $4.6B | $2.1B | 4.28 |
| 2025-06-30 | $10.9B | $1.6B | $2.8B | $4.4B | $1.9B | 4.28 |
| 2025-03-31 | $10.4B | $1.5B | $2.6B | $4.2B | $1.8B | 3.99 |
| Date | Name | Role | Shares | Value |
|---|---|---|---|---|
| 2026-04-27 | PETTITI GIANLUCA | President | 400 | $185.1K |
| 2026-03-11 | SHAFER MICHAEL D | Officer | 1,607 | $802.5K |
| 2026-03-05 | CASPER MARC N | Chief Executive Officer | 4,000 | $2.1M |
| 2026-03-05 | CASPER MARC N | Chief Executive Officer | 4,000 | $1.2M |
| 2026-03-04 | CASPER MARC N | Chief Executive Officer | 10,000 | $5.1M |
| 2026-03-04 | CASPER MARC N | Chief Executive Officer | 10,000 | $3.1M |
| 2026-02-25 | LAGARDE MICHEL | Chief Operating Officer | 2,231 | -- |
| 2026-02-25 | WILLIAMSON STEPHEN | Chief Financial Officer | 1,534 | -- |
| 2026-02-25 | BRITT LISA P | Officer | 2,045 | -- |
| 2026-02-25 | HOLMES JOSEPH R. | Officer | 770 | -- |
| Holder | Shares | Value | % Held |
|---|---|---|---|
| Blackrock Inc. | 30.4M | $13.6B | 0.1% |
| Vanguard Capital Management LLC | 24.3M | $10.9B | 0.1% |
| State Street Corporation | 16.7M | $7.5B | 0.0% |
| Morgan Stanley | 10.9M | $4.9B | 0.0% |
| FMR, LLC | 10.8M | $4.8B | 0.0% |
| Geode Capital Management, LLC | 8.4M | $3.8B | 0.0% |
| Franklin Resources, Inc. | 6.8M | $3.1B | 0.0% |
| JPMORGAN CHASE & CO | 6.8M | $3.0B | 0.0% |
| Capital World Investors | 6.6M | $3.0B | 0.0% |
| Price (T.Rowe) Associates Inc | 6.3M | $2.8B | 0.0% |
$206.6B
3.16
0.883
25
$45.2B
$43.2B
+11.3%
38.0%
1.41
2.43
0.0%
125,000
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| 2026-07-22 | $5.72 | Pending | — |
| 2026-04-23 | $5.24 | $5.44 | +3.8% |
| 2026-01-29 | $5.20 | $5.21 | +0.2% |
| 2025-10-22 | $5.50 | $5.79 | +5.3% |
| 2025-07-23 | $5.23 | $5.36 | +2.5% |
| 2025-04-23 | $5.10 | $5.15 | +0.9% |
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($611.56, 25 analysts) | |||
| 10 | $4,650.00 | +$1,465.60 (32%) | 2.1R |
| 50 | $23,250.00 | +$7,328.00 (32%) | 2.1R |
| 100 | $46,500.00 | +$14,656.00 (32%) | 2.1R |
| To Fair Value ($547.00) | |||
| 10 | $4,650.00 | +$820.00 (18%) | 1.2R |
| 50 | $23,250.00 | +$4,100.00 (18%) | 1.2R |
| 100 | $46,500.00 | +$8,200.00 (18%) | 1.2R |
- No elevated risk flags in current data
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| DHR | 0.775 |
| A | 0.749 |
| RVTY | 0.729 |
| MTD | 0.714 |
| IQV | 0.701 |
| Ticker | Correlation |
|---|---|
| SUKOON.AE | -0.141 |
| SEEF.BH | -0.139 |
| ATC.KW | -0.120 |
| NAPESCO.KW | -0.114 |
| PAVREIT.KL | -0.112 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.
How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.